https://doi.org/10.4081/hmr.v1i8.302

Oxaliplatin in lymphoma

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
Published: June 3, 2009
Abstract Views: 135
PDF: 839
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

C Haioun
support@pagepress.org
To day, 50 to 60% of patients with diffuse large cell lymphoma (DLCL) are cured by conventional chemotherapy but the outcome of patients who either fail to respond or relapse remains very poor. High dose therapy (HDT) followed by autologous stem cell support (ASCS) has become the standard option for such patients in failure. Complete response rates to fist-line treatment with anthracyclin-containing CHOP or CHOP-derived regimens are about 70%, with 5% toxic deaths, 10-15% partial responses and 10% primary failure. Among failures, relapses occurring in patients who first reached complete response are the most frequent event and despite salvage treatment have a 5y-survival of 30%-40%. Late relapses (occurring after one year of remission duration) have a better outcome than early relapses whose prognosis is close to that of primary failures.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Haioun, C. (2009). Oxaliplatin in lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.302
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).